IL-23: A Promising Therapeutic Target for Systemic Lupus Erythematosus

Archives of Medical Research

Volumn 41, Issue 3, 2010, Pages 221-225

  Leng, Rui Xue ^a   Pan, Hai Feng ^a   Chen, Gui Mei ^a   Wang, Chao ^a   Qin, Wei Zi ^a   Chen, Li Li ^a   Tao, Jin Hui ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

IL 23; IL 23 receptor; Systemic lupus erythematosus; Therapeutic target

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; STAT4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME ACTIVATION; HUMAN; INFLAMMATORY DISEASE; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL;

ANIMALS; AUTOIMMUNITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; INTERLEUKIN-23; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 77953512066     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.02.011     Document Type: Article

References (52)

1. Illei G.G., Tackey E., Lapteva L., et al. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 2004, 50:2048-2065.
2. Pan H.F., Ye D.Q., Li X.P. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008, 4:352-353.
3. Ooi J.D., Phoon R.K., Holdsworth S.R., et al. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 2009, 20:980-989.
4. Cua D.J., Sherlock J., Chen Y., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
5. Murphy C.A., Langrish C.L., Chen Y., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
6. Cargill M., Schrodi S.J., Chang M., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-290.
7. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
8. Oliver J., Rueda B., Lopez-Nevot M.A., et al. Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:977-981.
9. Cornelissen F., van Hamburg J.P., Lubberts E. The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis. Curr Opin Investig Drugs 2009, 10:452-462.
10. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006, 116:1218-1222.
11. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009, 183:3160-3169.
12. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
13. Bettelli E., Korn T., Oukka M., et al. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
14. Langrish C.L., McKenzie B.S., de Waal Wilson N.J., et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004, 202:96-105.
15. Kastelein R.A., Hunter C.A., Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007, 25:221-242.
16. Burton P.R., Clayton D.G., Cardon L.R., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337.
17. Sáfrány E., Pazár B., Csöngei V., et al. Variants of the IL23R gene are associated with ankylosing spondylitis but not with Sjögren syndrome in Hungarian population samples. Scand J Immunol 2009, 70:68-74.
18. Hölscher C. The power of combinatorial immunology: IL-12 and IL- 12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol (Berl) 2004, 193:1-17.
19. Yoshida A., Koide Y., Uchijima M., et al. IFN-γ induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem Biophys Res Commun 1994, 198:857-861.
20. Lankford C.S., Frucht D.M. A unique role for IL-23 in promoting cellular immunity. J Leukocyte Biol 2003, 73:49-56.
21. Oppmann B., Lesley R., Blom B., et al. Novel p19 protein engages IL- 12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
22. Hölscher C. Targeting IL-23 in autoimmunity. Curr Opin Investig Drugs 2005, 6:489-495.
23. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
24. Chen Z., Tato C.M., Muul L., et al. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007, 56:2936-2946.
25. Parham C., Chirica M., Timans J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R β1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002, 168:5699-5708.
26. Cheung P.F., Wong C.K., Lam C.W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 2008, 180:5625-5635.
27. Kanda N., Watanabe S. IL-12, IL-23, and IL-27 enhance human β-defensin-2 production in human keratinocytes. Eur J Immunol 2008, 38:1287-1296.
28. Jacobson N.G., Szabo S.J., Guler M.L., et al. Regulation of interleukin-12 signal transduction during T helper phenotype development. Res Immunol 1995, 146:446-456.
29. Elson C.O., Cong Y., Weaver C.T., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell mediated model in mice. Gastroenterology 2007, 132:2359-2370.
30. Harris T.J., Grosso J.F., Yen H.R., et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007, 179:4313-4317.
31. Mathur A.N., Chang H.C., Zisoulis D.G., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 2007, 178:4901-4907.
32. Yang X.O., Panopoulos A.D., Nurieva R., et al. STAT3 regulates cytokinemediated generation of inflammatory helper T cells. J Biol Chem 2007, 282:9358-9363.
33. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649.
34. Pène J., Chevalier S., Preisser L., et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008, 180:7423-7430.
35. McGeachy M.J., Bak-Jensen K.S., Chen Y., et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
36. Gocke A.R., Cravens P.D., Ben L.H., et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007, 178:1341-1348.
37. Egwuagu C.E., Sztein J., Mahdi R.M., et al. IFN-γ increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. J Immunol 1999, 162:510-517.
38. Haas C., Ryffel B., Le Hir M. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol 1997, 158:5484-5491.
39. Nakae S., Nambu A., Sudo K., et al. suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
40. Huber A.K., Jacobson E.M., Jazdzewski K., et al. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2008, 93:1077-1081.
41. Sutton C.E., Lalor S.J., Sweeney C.M., et al. Interleukin-1 and IL-23 induce innate IL-17 production from gamma delta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
42. Cheng F., Guo Z., Xu H., et al. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009, 68:604-606.
43. Liang S.C., Tan X.Y., Luxenberg D.P., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
44. Zheng Y., Danilenko D.M., Valdez P., et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
45. Wong C.K., Lit L.C., Tam L.S., et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in autoimmunity. Clin Immunol 2008, 127:385-393.
46. Huang X.F., Hua J., Shen N., et al. Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients. Mod Rheumatol 2007, 17:220-223.
47. Hillyer P., Larché M.J., Bowman E.P., et al. Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology 2009, 48:1581-1589.
48. Kwan B.C., Tam L.S., Lai K.B., et al. The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology 2009, 48:1491-1497.
49. Sanchez E., Rueda B., Callejas J.L., et al. Analysis of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus. Tissue Antigens 2007, 70:233-237.
50. Kim H.S., Kim I., Kim J.O., et al. No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. Rheumatol Int 2009, 30:33-38.
51. Mannon P.J., Fuss I.J., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004, 351:2069-2079.
52. Chen Y., Langrish C.L., McKenzie B., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006, 116:1317-1326.